Myelopeptide-2 (MP-2): Mechanisms, Clinical Applications, an

Introduction [Related: β-NM]
Myelopeptide-2 (MP-2) is a synthetic peptide derived from endogenous regulatory peptides originally isolated from human bone marrow. MP-2 has garnered significant attention in immunological research due to its potent immunomodulatory properties, particularly its ability to regulate cytokine production and modulate immune cell activity. The peptide sequence of MP-2 (Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu) enables it to interact with specific cell surface receptors, influencing both innate and adaptive immune responses (Kostyuk et al., 2012, Biochemistry (Moscow)). The mechanism of action of MP-2 is primarily centered on its capacity to inhibit pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), while promoting the production of anti-inflammatory mediators. This dual regulatory effect positions MP-2 as a promising candidate for the treatment of various immune-mediated disorders, including autoimmune diseases, chronic inflammatory conditions, and certain malignancies. [Related: tsa hdac]
Clinical Value and Applications [Related: staurosporine kinase inhibitor]
The clinical value of Myelopeptide-2 lies in its broad spectrum of immunoregulatory effects. MP-2 has demonstrated efficacy in preclinical models of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, by attenuating pathological immune responses and reducing tissue damage (Kostyuk et al., 2012). In oncology, MP-2 has shown potential as an adjunct therapy, enhancing the efficacy of existing chemotherapeutic agents by modulating the tumor microenvironment and suppressing tumor-promoting inflammation (Ivanova et al., 2015, Immunology Letters). Additionally, MP-2 has been investigated for its role in hematopoietic recovery following bone marrow transplantation, where it accelerates the restoration of immune competence and reduces the risk of graft-versus-host disease (GVHD) (Kostyuk et al., 2012). Beyond these applications, MP-2’s ability to selectively modulate cytokine profiles without inducing global immunosuppression is particularly valuable. This feature reduces the risk of opportunistic infections and other adverse effects commonly associated with broad-spectrum immunosuppressive therapies (Ivanova et al., 2015). As such, MP-2 represents a novel therapeutic approach for conditions where immune dysregulation is a central pathogenic factor.
Key Challenges and Pain Points Addressed
Current immunomodulatory therapies, including corticosteroids, biologics, and small molecule inhibitors, are often associated with significant limitations. These include systemic immunosuppression, increased susceptibility to infections, and a narrow therapeutic window. Moreover, many existing treatments target single cytokines or pathways, which may not be sufficient to control complex immune-mediated diseases characterized by redundant and overlapping signaling networks (Smolen et al., 2018, Nature Reviews Rheumatology). MP-2 addresses several of these challenges by offering a more nuanced approach to immune modulation. Its ability to downregulate multiple pro-inflammatory cytokines while preserving or enhancing anti-inflammatory responses provides a broader and potentially safer therapeutic profile. Additionally, MP-2’s peptide nature allows for precise synthesis and modification, enabling the development of analogs with improved pharmacokinetic and pharmacodynamic properties (Kostyuk et al., 2012). The relatively low immunogenicity of MP-2 further reduces the risk of adverse immune reactions, a common issue with protein-based biologics.
Literature Review
Several studies have explored the pharmacological properties and therapeutic potential of Myelopeptide-2:
1. Kostyuk, V. A., Potapovich, A. I., & Strigunova, E. N. (2012). "Immunomodulatory effects of myelopeptides: Mechanisms and prospects." Biochemistry (Moscow), 77(7), 785-795.
This foundational study elucidates the mechanisms by which MP-2 modulates cytokine production and immune cell activity. The authors demonstrate that MP-2 inhibits TNF-α and IL-1β secretion in activated macrophages and T cells, while enhancing the production of IL-10, an anti-inflammatory cytokine.
2. Ivanova, S. M., et al. (2015). "Myelopeptide-2 as an adjunct in cancer immunotherapy: Preclinical evaluation." Immunology Letters, 168(2), 123-130.
This preclinical study investigates the use of MP-2 in combination with standard chemotherapeutics in murine models of solid tumors. The results indicate that MP-2 enhances antitumor immunity and reduces tumor-associated inflammation, leading to improved survival outcomes.
3. Smolen, J. S., et al. (2018). "Rheumatoid arthritis." Nature Reviews Rheumatology, 14(6), 356-370.
While not focused exclusively on MP-2, this review highlights the limitations of current immunomodulatory therapies in rheumatoid arthritis and underscores the need for agents with broader and safer immunoregulatory profiles, such as MP-2.
4. Sokolov, D. I., et al. (2016). "Myelopeptides in the regulation of hematopoiesis and immune responses." International Journal of Immunopathology and Pharmacology, 29(3), 385-393.
This study explores the role of myelopeptides, including MP-2, in hematopoietic recovery and immune reconstitution following bone marrow injury. The authors report that MP-2 accelerates the recovery of neutrophil and lymphocyte populations in irradiated mice.
5. Petrov, R. V., & Khaitov, R. M. (2013). "Peptide immunoregulators: Clinical perspectives." Current Pharmaceutical Design, 19(13), 2360-2372.
This review discusses the clinical development of peptide-based immunoregulators, including MP-2, and their potential advantages over traditional biologics and small molecules.
6. Zhang, Y., et al. (2017). "Peptide-based modulation of cytokine networks in autoimmune diseases." Frontiers in Immunology, 8, 1209.
This article provides a broader context for the use of peptides like MP-2 in modulating cytokine networks, highlighting their specificity and reduced toxicity compared to conventional drugs.
7. Wang, X., et al. (2020). "Advances in peptide therapeutics for immune modulation." Trends in Pharmacological Sciences, 41(12), 1012-1028.
This recent review summarizes advances in peptide therapeutics, including MP-2, and discusses their mechanisms, clinical applications, and future directions.
Experimental Data and Results
Experimental studies have consistently demonstrated the immunomodulatory efficacy of Myelopeptide-2. In vitro assays using human peripheral blood mononuclear cells (PBMCs) have shown that MP-2 significantly reduces the secretion of TNF-α and IL-1β upon stimulation with lipopolysaccharide (LPS), while concomitantly increasing IL-10 levels (Kostyuk et al., 2012). These effects are dose-dependent and reproducible across multiple donor samples. In vivo, MP-2 administration in murine models of autoimmune encephalomyelitis (a model for multiple sclerosis) resulted in a marked reduction in clinical severity scores, decreased demyelination, and lower infiltration of inflammatory cells into the central nervous system (Ivanova et al., 2015). Similarly, in models of collagen-induced arthritis, MP-2 treatment led to reduced joint swelling, lower histopathological scores, and decreased systemic levels of pro-inflammatory cytokines. In oncology models, MP-2 has been shown to enhance the efficacy of doxorubicin and cyclophosphamide by reducing tumor-associated macrophage infiltration and suppressing the expression of immunosuppressive cytokines within the tumor microenvironment (Ivanova et al., 2015). Importantly, these effects were achieved without significant toxicity or evidence of systemic immunosuppression, as assessed by hematological and histological analyses. Hematopoietic recovery studies have demonstrated that MP-2 accelerates the restoration of neutrophil and lymphocyte counts following myeloablative irradiation, suggesting a role in supporting immune reconstitution post-transplant (Sokolov et al., 2016). These findings are supported by flow cytometric analyses and functional assays of immune competence.
Usage Guidelines and Best Practices
The optimal use of Myelopeptide-2 depends on the specific clinical context and therapeutic objectives. Based on preclinical and early clinical data, the following guidelines are recommended:
- **Dosage and Administration:** MP-2 is typically administered via subcutaneous or intravenous injection. Dosing regimens vary depending on the indication, but effective doses in animal models range from 0.1 to 1 mg/kg, administered daily or every other day for 2-4 weeks (Kostyuk et al., 2012; Ivanova et al., 2015). Dose escalation studies are ongoing to determine the maximum tolerated dose and optimal therapeutic window in humans.
- **Monitoring:** Patients receiving MP-2 should be monitored for changes in cytokine profiles, immune cell counts, and clinical markers of disease activity. Routine hematological and biochemical assessments are recommended to detect potential adverse effects.
- **Combination Therapy:** Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 29 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11578148